Quantcast
Last updated on April 19, 2014 at 7:50 EDT

Latest TNF inhibitor Stories

2012-09-28 10:23:16

ABBOTT PARK, Ill., Sept. 28, 2012 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved HUMIRA(®) (adalimumab) for inducing and sustaining clinical remission in adult patients with moderately to severely active ulcerative colitis (UC) when certain other medicines have not worked well enough. Combined with its approval to treat moderate to severe Crohn's disease, HUMIRA is now approved for the treatment of two primary diseases...

2012-09-18 10:25:22

HORSHAM, Pa., Sept. 18, 2012 /PRNewswire/ -- Janssen Biotech, Inc. announced today the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) requesting approval of an investigational intravenous formulation of the anti-tumor necrosis factor (TNF)-alpha SIMPONI(®) (golimumab) for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). An estimated 1.5 million Americans are living with RA,[1] a chronic autoimmune...

2012-09-17 22:21:22

LEXINGTON, Mass., Sept. 18, 2012 /PRNewswire/ -- Avaxia Biologics, Inc., a privately-held biotechnology company developing oral antibody drugs that act locally within the digestive tract, announced today that the company was awarded U.S. Patent 8,268,971, entitled "Antibody Therapy for Modulating Function of Intestinal Receptors and Methods of Treating Diabetes and Obesity." The patent covers milk derived antibody compositions that specifically target and modulate an apical intestinal...

2012-08-23 02:26:05

CORK, Ireland and SPRING HOUSE, Pa., Aug. 23, 2012 /PRNewswire/ -- Janssen Biologics (Ireland) announced today it has initiated the Phase 3 development program for sirukumab (CNTO 136) as part of a collaboration with GlaxoSmithKline plc (GSK). Sirukumab is a human anti-interleukin (IL)-6 monoclonal antibody being studied for the treatment of adults with moderately to severely active rheumatoid arthritis (RA). "We are focused on advancing treatment options for chronic, debilitating...

2012-08-21 21:47:57

Use of tumor necrosis factor (TNF) inhibitors for treatment of psoriasis is associated with a significantly reduced risk for heart attack (myocardial infarction) compared to other forms of treatment, according to a report published Online First by Archives of Dermatology, a JAMA Network publication. "The effect of systemic treatment for psoriasis on cardiovascular disease has been largely unexplored," the authors write as background information in the study. "The primary objective of this...

2012-08-08 22:21:16

Study compares overall mortality in TNF inhibitors: Humira, Enbrel, and Remicade New research confirms no significant difference in the rates of death among patients with rheumatoid arthritis (RA) who were exposed to one of several TNF inhibitors used to treat RA, adalimumab (Humira), etanercept (Enbrel), and infliximab (Remicade). This population-based study of RA patients in Sweden–the first to compare mortality rates among patients treated with individual TNF inhibitors–is...

2012-08-07 07:41:59

Adalimumab (an anti-tumor necrosis factor [TNF] antibody) is effective in maintaining remission in certain pediatric patients with Crohn's disease, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association. Steroids are commonly used in Crohn's disease, but can stunt growth and delay puberty. Incidence of this disease, which causes intestinal inflammation, is on the rise in children. This study is the largest double-blind study of...

2012-07-16 10:25:29

HORSHAM, Pa. and LEIDEN, Netherlands, July 16, 2012 /PRNewswire/ -- Janssen Biotech, Inc. and Janssen Biologics B.V. announced today the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) requesting approval of SIMPONI® (golimumab) for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response to...

2012-06-25 23:01:25

A novel anti-inflammatory approach produced a significant reduction in stroke size and neural deficit in an animal model. The animal study follows publication by the INR (CNS Drugs, 2011. 25(2):145) of pioneering human data that utilized a related anti-inflammatory approach and underscores the promise of this concept. Source: Institute of Neurological Recovery, Los Angeles Los Angeles, California (PRWEB) June 25, 2012 New evidence supporting the potential value of a new type of...

2012-06-08 13:33:04

New study validates score as new tool Results of a study presented today at EULAR 2012, the Annual Congress of the European League Against Rheumatism, suggest that the newly developed RABBIT Risk Score, which calculates the risk of serious infections in patients with rheumatoid arthritis (RA) who are treated with anti-tumor necrosis factor drugs (anti-TNFs) or conventional disease modifying anti-rheumatic drugs (DMARDs) is a valid and effective tool for rheumatologists to predict risk of...